Preventing Cardiovascular Events in Our Patients With PCSK9 Inhibition

Release Date: May 19, 2021
Expiration Date: May 19, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in cardiovascular disease. In this educational program, these experts use a case-based format to discuss the latest evidence and guidelines regarding cardiovascular risk reduction, particularly strategies for secondary prevention in patients at high risk who are likely to benefit from non-statin therapies such as PCSK9 inhibitors.
 
This educational activity is an archive of the live virtual symposium held on April 30, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.
 

Target Audience

This educational activity is directed toward general internists and internal medicine subspecialists who treat patients with lipid disorders. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in lipid management are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to

• Identify patients most likely to benefit from the addition of non-statin therapies to their treatment regimen
• Assess recent efficacy and safety data and guideline recommendations for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for cardiovascular risk reduction in patients who have not achieved lipid treatment goals
• Select appropriate therapies for patients with cardiovascular risk who are not at lipid treatment goals, based on patient-centered considerations
• Analyze current evidence regarding the relationship between cost-effectiveness data and access barriers for PCSK9 inhibitors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Associate Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, CA

Disclosures: Grant Research Support: Amgen, Applied Therapeutics, Federal Emergency Management Agency, National Institutes of Health; Consultant: Amgen, Boehringer Ingelheim, Esperion Therapeutics, Novo Nordisk, Sanofi/Regeneron

Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health
Portland, OR

Disclosures: Ty J. Gluckman has no relevant financial relationships with ineligible companies.

Brett Nowlan, MD, FACC
Noninvasive Cardiologist and Lipidologist
Cottage Grove Cardiology
Bloomfield, CT

Disclosures:Speakers Bureau: Amgen

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.